Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2301 to 2350 of 8236 results

  1. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]

    Awaiting development Reference number: GID-TA10777 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Vamikibart for treating uveitic macular oedema [ID6671]

    Awaiting development Reference number: GID-TA11885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTE10083 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  4. Efzimfotase alfa for treating hypophosphatasia in people 12 years and over [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]

    Awaiting development Reference number: GID-TA11847 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. UX111 for treating mucopolysaccharidosis type IIIA [ID6540]

    Awaiting development Reference number: GID-TA11701 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Bladder cancer: diagnosis and management (update)

    In development Reference number: GID-NG10452 Expected publication date: TBC

    NICE guideline
    In development

  10. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date: TBC

    NICE guideline
    In development

  11. Fenebrutinib for treating relapsing multiple sclerosis [ID6577]

    Awaiting development Reference number: GID-TA11775 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]

    Awaiting development Reference number: GID-TA11744 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    Awaiting development Reference number: GID-TA11743 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

    Awaiting development Reference number: GID-TA11667 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  16. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  17. Ruxolitinib for Prurigo Nodularis [ID6571]

    In development Reference number: GID-TA11760 Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11720 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Elinzanetant for Vasomotor symptoms [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date:  21 July 2027

    Technology appraisal guidance
    Awaiting development

  20. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  21. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    Awaiting development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351

    In development Reference number: GID-TA11333 Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]

    In development Reference number: GID-TA11630 Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Thermal Probe Ablation for abdominal wall endometriosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  25. Mercaptamine hydrochloride for treating corneal cystine crystal deposits in people 6 months to under 2 years with cystinosis [TSID12261]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  26. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    In development Reference number: GID-TA11633 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development

  27. Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

    In development Reference number: GID-TA11116 Expected publication date:  29 July 2026

    Technology appraisal guidance
    In development

  28. Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension

    In development Reference number: GID-IPG10318 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  29. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments ID6413

    In development Reference number: GID-TA11488 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  30. Pegzilarginase for treating arginase-1 deficiency [ID4029]

    In development Reference number: GID-HST10054 Expected publication date:  20 February 2026

    Highly specialised technologies guidance
    In development

  31. Technologies to support the rapid diagnosis of endometriosis (provisional title)

    In development Reference number: GID-HTE10082 Expected publication date: TBC

    Health technology evaluations
    In development

  32. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363

    In development Reference number: GID-TA11422 Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Orforglipron for managing overweight and obesity ID6516

    In development Reference number: GID-TA11650 Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. Robotic surgery for paediatric population

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  35. Orbital atherectomy for calcified coronary artery disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  36. NeuroSAFE for Intra-operative frozen section evaluation of neurovascular bundle adjacent prostate capsule during radical prostatectomy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  37. Bioinductive collagen scaffold (Regeneten) for rotator cuf repair

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  38. Intradiscal Platelet Rich Plasma (PRP) Injections for Back Pain with Modic Type 1 Changes

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  39. Cardiac ablation with percutaneous left atrial appendage occlusion (LAAO) for atrial fibrillation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  40. Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  41. Selective internal radiation therapy for unresectable colorectal metastases in the liver

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  42. Hip resurfacing for hip arthritis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  43. Botulinum toxin injection to cricopharyngeal muscle for retrograde cricopharyngeal dysfunction (RCPD)

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  44. Transoral endoscopic thyroid surgery via a vestibular approach

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  45. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism

    Awaiting development Reference number: GID-IPG10456 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  46. Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA)

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  47. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-IPG10392 Expected publication date: TBC

    Interventional procedures guidance
    In development

  48. Meniscal Allograft Transplantation for symptomatic meniscal deficient knee

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  49. Excimer Laser Trabeculotomy (ELT) for glaucoma

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  50. CT guided fibrin glue sealing of CSF leak to treat spontaneous intracranial hypotension

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation